УДК 616.366-003.7-053.2]-616-092-08

Original research

THE LEVEL OF ZINC IN BLOOD PLASMA AND THE COURSE OF GALLSTONE DISEASE IN CHILDREN

T.V. Sorokman, V.G. Ostapchuk

Bukovinian State Medical University

Key words: children, biliary tract dysfunction, gallstone disease, clinical and laboratory course, zinc.

Bukovinian Medical Herald.

2023. V. 27, № 1 (105). P. 61-66.

DOI: 10.24061/2413-0737.27.1.105.2023.11

E-mail: t.sorokman@gmail.com Determining the zinc level in children's blood plasma is an urgent problem, given its possible participation in the formation of cholelithiasis.

Aim. To investigate the level of zinc in the blood plasma and the clinical course of gallstone disease (GSD) in children.

Methods. 69 children aged 10-17 years and 25 children without biliary tract pathology were selected by the method of simple randomization. Verification of the diagnosis was carried out by applying dynamic ultrasound examination and X-ray examination of the organs of the abdominal cavity. Quantitative determination of zinc in blood plasma was carried out using mass spectrometry.

Results. Dysfunction of the biliary tract according to the hyperkinetic type occurred in $55.1\pm7.1\%$ of children and according to the hypokinetic type in $44.9\pm3.9\%$. The asymptomatic variant of housing and communal services was observed in 23.9%, painful - in 54.3% of patients, paroxysmal - in 21.7% of patients. The plasma concentration of zinc in children with gastrointestinal diseases was 1.87 times lower than in children of the comparison group and 1.37 times lower than in children with hyperkinetic gallbladder dysfunction, while there was a probable difference between these indicators in children with housing and communal services and in children with the hypotonic type of gallbladder dysfunction (p<0.05).

Conclusions. 1. The leading syndromes of gallstone disease in children were pain and dyspepsia. 2. Gallstone disease in children occurs against the background of gallbladder dysfunction with a predominance of the painful course, the formation of solitary bilirubin-derived concretions and minor changes in biochemical blood analysis. 3. The concentration of zinc in the blood plasma of children with gallstone disease is probably lower than in children of the comparison group and does not depend on age and gender.

РІВЕНЬ ЦИНКУ В ПЛАЗМІ КРОВІ ТА ПЕРЕБІГ ЖОВЧНОКАМ'ЯНОЇ ХВОРОБИ У ДІТЕЙ

Т.В. Сорокман, В.Г. Остапчук

Ключові слова: діти, дисфункція біліарного тракту, жовчнокам'яна хвороба, клінічнолабораторний перебіг, цинк.

Буковинський медичний вісник. 2023. Т. 27, № 1 (105). С. 61-66. Визначення рівня цинку в плазмі крові дітей є актуальною проблемою з огляду на його можливу участь у формуванні холелітіазу.

Мета. Дослідити рівень цинку в плазмі крові та клінічний перебіг жовчнокам'яної хвороби (ЖКХ) у дітей.

Матеріал і методи. Методом простої рандомізації відібрано 69 дітей віком 10-17 років та 25 дітей без патології біліарного тракту. Верифікація діагнозу проводилася з використанням динамічного ультразвукового дослідження та оглядової рентгенографії органів черевної порожнини. Кількісне визначення цинку в плазмі крові здійснювали за допомогою мас-спектрометрії.

Результати. Дисфункція біліарного тракту за гіперкінетичним типом траплялася у 55,1 \pm 7,1% дітей та за гіпокінетичним типом у 44,9 \pm 3,9%. Асимптомний варіант ЖКХ спостерігався у 23,9%, больовий - у 54,3% хворих, нападоподібний - у 21,7 % хворих. Плазмова концентрація цинку в дітей, хворих на ЖКХ, була в 1,87 раза нижчою, ніж у дітей групи порівняння та в 1,37 раза нижчою ніж у дітей із дисфункцією жовчного міхура за гіперкінетичним типом типом, тоді як вірогідної різниці між цими показниками у дітей, хворих на ЖКХ та у дітей із дисфункцією жовчного міхура за гіпотонічним типом не виявлено (p<0,05).

Висновки. 1. Провідними синдромами жовчнокам'яної хвороби в дітей больовий та диспепсичний. 2. Жовчнокам'яна хвороба в дітей проходить на

http://e-bmv.bsmu.edu.ua

Оригінальні дослідження

тлі дисфункції жовчного міхура з переважанням больового варіанта перебігу, утворенням одиноких білірубінового походження конкрементів та незначних змін біохімічного аналізу крові. З.Концентрація цинку в плазмі крові дітей, хворих на жовчнокам'яну хворобу, вірогідно нижча, ніж у дітей групи порівняння та не залежала від віку та статі.

Introduction. The frequency of diseases of the hepatobiliary system among the pathologies of the digestive organs in children is 1-2%, while its constant growth is noted every year [1]. Diseases of the biliary tract, as a rule, attract the attention of specialists in "adult" practice [4]. The incidence of gallstone disease is 10-20% of the adult population [5, 6] and up to 1% of the children's population [7-9]. However, this problem is becoming more and more relevant in pediatrics as even in newborn children, gallstones are becoming more and more common [10-12].

The prevalence of gallstone disease among children is not exactly known, according to some data it is from 0.1 to 1% [13-15]. Gallstone disease occurs more often in schoolaged children, among children up to 7 years old, boys are twice as often affected as girls, at the age of 7-9 years there are no gender differences in the frequency of the disease, at the age of 10-12 years, girls are affected twice as often as boys. Most children have bilirubin calculi before puberty, and cholesterol calculi in puberty and adolescence [16, 17, 18]. Dyscholia of hepatic genesis, cholestasis and inflammation are the main factors in the formation of cholelithiasis in children. As a result of a genetic or acquired defect, the ratio of the main components of bile, which are synthesized in the liver, is disturbed - the liver produces lithogenic bile [19, 20]. It has been proven that an elevated level of zinc plays a certain role in the formation of stones in the gallbladder, as it is known about its ability to activate crystallization processes in certain concentrations [21, 22]. Therefore, the determination of the level of zinc in children's blood plasma is an urgent problem in view of its possible participation in the formation of cholelithiasis.

Aim. To investigate the level of zinc in blood plasma and the clinical course of gallstone disease in children.

Methods. By the method of simple randomization, 69 children aged 10-17 years were selected, pre-stratified according to the presence of biliary tract dysfunction and stones in the gall bladder, of which 46 children had the disease code according to ICD-10 – K80. The comparison group consisted of 25 children of the appropriate age without biliary tract pathology.

The cumulative frequency of complaints for each child was evaluated separately with the following gradation: periodic complaints were evaluated with a coefficient of 0.3, frequent complaints with a coefficient of 0.5, absence of complaints with a coefficient of 0.0 (maximum 2.5 points). The expression of clinical symptoms was evaluated according to the point system (from 1 to 3 points). The objective examination was carried out according to generally accepted clinical methods (palpation and percussion of the anterior abdominal wall, symptoms of G. Kerr, J. Murphy, N. Ortner were determined). Verification of the diagnosis was carried out in accordance with the unified clinical protocol [22] with the use of dynamic ultrasound examination and X-ray examination of the abdominal organs to determine the Xray contrast of the calculi.

Blood sampling was carried out in the procedure room from the elbow vein in the morning on an empty stomach in a volume of at least 5 ml in a regular glass tube without the use of a coagulation activator. After centrifugation, the plasma was transferred to test tubes and stored at a temperature of -70 °C until analysis. Biochemical analysis of blood was carried out according to generally accepted methods. Quantitative determination of zinc in blood plasma was carried out using inductively coupled plasma mass spectrometry (MS-ICP) on an Optima 2000 DV spectrometer (PerkinElmer, USA). The concentration was estimated in $\mu g/l$.

Data from clinical observations were statistically processed on a computer using Microsoft Excel 2010, Statistica 6.1 licensed programs. To evaluate the research results, the following indicators were studied: sufficient sample size (n), arithmetic mean (M), mean square deviation (sx), coefficient of variation (Cv), error of the mean square deviation (m), confidence limits and reliable difference of the difference of results. The averaged data are given as M \pm m, where M is the arithmetic mean value, m is the error of the arithmetic mean. The normality of the distribution of indicators was assessed using the Shapiro-Wilk W-test. To reveal the statistical difference between indicators in normally distributed groups, the Student's t-criterion of reliability was used, the degree of significance - p.

Results and discussion. The average coefficient of the frequency of complaints for each child was 0.8. In 18.9% of children, the total coefficient did not exceed 0.6, that is, the presence of complaints was sporadic, in the remaining 71.0% of the interviewed children, the frequency coefficient of complaints exceeded 1.1. More often, children complained of abdominal pain, which occurred in 78.3% of cases. Complaints about frequent abdominal pain were expressed by 4.1% of the interviewed children, 74.2% noted periodic abdominal pain. The second most frequent complaint was burping, which was often observed in 13.2% of children and occasionally in 52.7%. In third place were complaints of nausea - 52.7%. At the same time, nausea was often observed in 4.3% of children, periodically in 48.8% of children. Vomiting was observed in almost a third of children (28.9%), frequent episodes of vomiting were observed in 5.7% of children, periodic episodes in 23.2% of children. Heartburn was recorded in 20.3% of children (Fig. 1)

During objective examination in children, the liver protruded from under the edge of the right costal arch by 1.5-2.0 cm, its surface was smooth. The consistency was soft-elastic, the edge -sharp. All children had a positive.




Fig. 1. Frequency of clinical symptoms in children with functional disorders of the biliary tract

Ortner symptom. Among the examined children, dysfunction of the biliary tract according to the hyperkinetic type occurred in $55.1\pm7.1\%$ of children (n=38) and according to the hypokinetic type in $44.9\pm3.9\%$ (n=31). The distribution of children with various types of biliary tract dysfunction by age is presented in Table 1.

In children aged 10-14 years, the hypokinetic variant of gallbladder dysfunction occurred more often $(77.4\pm5.6\%)$, while among children aged 14-17 years - hyperkinetic variant (73.7±6.3%). Girls predominate among the examined children - 56.5±7.9%. Out of 69 examined children, 46 (66.6%) were confirmed to have gallstone disease (gallstone disease). Clinical and laboratory characteristics of GSD in children are presented in Table 2. According to the stage of GSD, the children were distributed as follows: II stage - 80.4% (n=37), III stage -19.6% (n=9). In the clinical picture of the disease, three clinical variants of the course of the disease are distinguished: the asymptomatic variant of GSD was observed in 23.9%, the painful variant of GSD - in 54.3%of patients, the paroxysmal variant of GSD with biliary colic - in 21.7% of patients. The second stage of gastrointestinal tract with single concretions, which were of pigment origin and most often localized in the gallbladder, was recorded more often. More than half of the examined children were characterized by s-shaped deformation of the gallbladder. In the biochemical blood analysis, a third of the children had an increased level of total bilirubin due to both direct and indirect factors, and some children had an increase in alkaline phosphatase and a violation of the lipid profile.

The average level of zinc in blood plasma in children with biliary tract dysfunction was 2.55 ± 0.62 mg/l, in children of the comparison group — 3.98 ± 0.69 (p< 0.05). We did not establish gender and age differences in zinc levels in blood plasma (Fig. 2).

Table 1 viliary

Distribution of children with various types of biliary tract dysfunction by age

tract dystanction by age								
	Hyperkinetic		Dysfunction by					
Age (years)	dysfunction, n=38		hypokinetic type, n=31					
	n	%	n	%				
10-12	10	26,3	13	41,9				
13-14	13	34,2	11	35,4				
15-17	15	39,5	7	22,5				
Total	38	100	31	100				

Table 2	2				
Clinical and laboratory characteristics of GSD in					
childron					

Variant of the course of the disease asymptomatic 11 23,9 painful 25 54,3 offensive 7 15,2 dyspeptic 3 6,5 Stages I 9 19,6 II 24 52,1 III 13 28,3 The number of calculi single 39 84,8 multiple 7 15,2 Origin - - - cholesterol 19 41,3 - pigmented 20 44,4 - mixed 7 15,2 - Localization - 15,2 - in the gall bladder 30 65,2 - in the common bile duct 15 32,6 - in the common bile duct 15 32,6 - in the common bile duct 14 8,7 - Body 8 17,4 -	children						
asymptomatic 11 23,9 painful 25 54,3 offensive 7 15,2 dyspeptic 3 6,5 Stages I 9 19,6 II 24 52,1 III 24 52,1 III 13 28,3 The number of calculi single 39 84,8 multiple 7 15,2 Cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 1 2,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder 50,9 60,9 s-like 28 60,9 otal lipidogram (mg/100ml) Indicator M±m Indicator M±	Indicators		%				
painful 25 54,3 offensive 7 15,2 dyspeptic 3 6,5 Stages I 9 19,6 II 24 52,1 III 13 28,3 The number of calculi 39 84,8 multiple 7 15,2 Origin 7 15,2 cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 1 2,2 In the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder 50,9 60,9 body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Biochemical indicators of blood Lipidogram (mg/100T) <td< td=""><td colspan="6"></td></td<>							
offensive 7 15,2 dyspeptic 3 6,5 Stages 1 9 19,6 II 24 52,1 III 13 28,3 The number of calculi 39 84,8 multiple 7 15,2 Origin 7 15,2 Cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 1 2,2 In the gall bladder 30 65,2 in the common bile duct 15 32,6 in the common bile duct 1 2,2 Deformation of the gallbladder 50,9 60,9 body 8 17,4 neck 6 13,0 s-like 28 60,9 <		11					
dyspeptic 3 6,5 Stages 9 19,6 II 24 52,1 III 13 28,3 The number of calculi 39 84,8 multiple 7 15,2 Origin 7 15,2 Cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 1 2,2 in the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder 53,4 body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Jphospholipids 159,9±4,7 free cholesterol 49,9±2,2 non-esterified fatty acids 58,8±6,1 triglycerides 17,2±9,7 cholesterol esters		25					
Stages I 9 19,6 II 24 52,1 III 13 28,3 The number of calculi 39 84,8 multiple 7 15,2 Origin 7 15,2 Cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 1 2,2 in the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder 30 65,2 body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Biochemical indicators of blood Lipidogram (mg/100ml) Indicator M±m total lipids 58,8±6,1 triglycerides 17,2±9,7 cholesterol esters 101,3		7					
I 9 19,6 II 24 52,1 III 13 28,3 The number of calculi 39 84,8 multiple 7 15,2 Origin 7 15,2 cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 1 2,2 in the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Biochemical indicators of blood Lipidogram (mg/100ml) Indicator M±m total lipids 659,3±17,3 phospholipids 159,9±4,7 free cholesterol 49,9±2,2 non-esterified fatty acids 58,8±6,1 triglycerides 17,5,2±9,7 cholesterol esters <td>dyspeptic</td> <td>3</td> <td>6,5</td>	dyspeptic	3	6,5				
II 24 52,1 III 13 28,3 The number of calculi 39 84,8 multiple 7 15,2 Origin 7 15,2 cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 15 32,6 in the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Biochemical indicators of blood Lipidogram (mg/100ml) Indicator M±m total lipids 659,3±17,3 phospholipids 159,9±4,7 free cholesterol 49,9±2,2 non-esterified fatty acids 58,8±6,1 triglycerides 17,5,2±9,7 cholesterol esters 101,3±4,5 Bilirubin, mmol/I t	Stages						
III 13 28,3 The number of calculi single 39 84,8 multiple 7 15,2 Origin cholesterol 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization in the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder 53,0 65,2 body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Biochemical indicators of blood Lipidogram (mg/100ml) Indicator M±m total lipids 659,3±17,3 phospholipids 159,9±4,7 free cholesterol 49,9±2,2 non-esterified fatty acids 58,8±6,1 triglycerides 175,2±9,7 cholesterol esters 101							
The number of calculisingle3984,8multiple715,2Origincholesterol1941,3pigmented2044,4mixed715,2Localizationin the gall bladder3065,2in the common bile duct1532,6in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour4Biochemical indicators of bloodLipidogram (mg/100ml)Itipidogram (mg/100ml)IndicatorM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/I24,8±6,1direct fraction17,9±3,4indirect fraction7,8±1,1Enzymes, U/IAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1	II						
single 39 84,8 multiple 7 15,2 Origin 19 41,3 pigmented 20 44,4 mixed 7 15,2 Localization 7 15,2 in the gall bladder 30 65,2 in the common bile duct 15 32,6 in the hepatic ducts 1 2,2 Deformation of the gallbladder 0 65,2 body 8 17,4 neck 6 13,0 s-like 28 60,9 contour 4 8,7 Biochemical indicators of blood Lipidogram (mg/100ml) Indicator M±m total lipids 659,3±17,3 phospholipids 159,9±4,7 free cholesterol 49,9±2,2 non-esterified fatty acids 58,8±6,1 triglycerides 175,2±9,7 cholesterol esters 101,3±4,5 Bilirubin, mmol/I 24,8±6,1 direct fraction <td< td=""><td></td><td>13</td><td>28,3</td></td<>		13	28,3				
multiple715,2Origincholesterol1941,3pigmented2044,4mixed715,2Localizationin the gall bladder3065,2in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour4M±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterolM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/Itotal bilirubin24,8±6,1direct fraction17,9±3,4indirect fraction7,8±1,1Enzymes, U/IAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1							
Origincholesterol1941,3pigmented2044,4mixed715,2Localizationin the gall bladder3065,2in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/I24,8±6,1direct fraction7,8±1,1Enzymes, U/IAlanine aminotransferaseAspartate transaminase27,9±1,1		39					
cholesterol1941,3pigmented2044,4mixed715,2Localizationin the gall bladder3065,2in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/I24,8±6,1direct fraction7,8±1,1Enzymes, U/IAlanine aminotransferaseAspartate transaminase27,9±1,1	multiple	7	15,2				
pigmented2044,4mixed715,2Localizationin the gall bladder3065,2in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour48,7Biochemical indicators of bloodItipidogram (mg/100ml)IndicatorM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/I24,8±6,1direct fraction7,8±1,1Enzymes, U/IAlanine aminotransferaseAspartate transaminase27,9±1,1	Origin						
mixed715,2Localizationin the gall bladder30 $65,2$ in the common bile duct15 $32,6$ in the hepatic ducts1 $2,2$ Deformation of the gallbladderbody8 $17,4$ neck6 $13,0$ s-like28 $60,9$ contour4 $8,7$ Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $7,8\pm1,1$ Enzymes, U/IAlanine aminotransferaseAspartate transaminase $27,9\pm1,1$		-					
Localizationin the gall bladder3065,2in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour48,7Biochemical indicators of blood1Lipidogram (mg/100ml)IndicatorIndicatorM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/I17,9±3,4indirect fraction7,8±1,1Enzymes, U/IEnzymes, U/IAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1	pigmented	20	44,4				
in the gall bladder30 $65,2$ in the common bile duct15 $32,6$ in the hepatic ducts1 $2,2$ Deformation of the gallbladderbody8 $17,4$ neck6 $13,0$ s-like28 $60,9$ contour4 4 $8,7$ Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $7,8\pm1,1$ Enzymes, U/I $Alanine aminotransferase$ Aspartate transaminase $27,9\pm1,1$		7	15,2				
in the common bile duct1532,6in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour4Riochemical indicators of bloodLipidogram (mg/100ml)IndicatorM \pm mtotal lipids659,3 \pm 17,3phospholipids159,9 \pm 4,7free cholesterol49,9 \pm 2,2non-esterified fatty acids58,8 \pm 6,1triglycerides175,2 \pm 9,7cholesterol esters101,3 \pm 4,5Bilirubin, mmol/I24,8 \pm 6,1direct fraction17,9 \pm 3,4indirect fraction7,8 \pm 1,1Enzymes, U/IAlanine aminotransferaseAspartate transaminase27,9 \pm 1,1							
in the hepatic ducts12,2Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM \pm mtotal lipids659,3 \pm 17,3phospholipids159,9 \pm 4,7free cholesterol49,9 \pm 2,2non-esterified fatty acids58,8 \pm 6,1triglycerides175,2 \pm 9,7cholesterol esters101,3 \pm 4,5Bilirubin, mmol/I17,9 \pm 3,4indirect fraction7,8 \pm 1,1Enzymes, U/IEnzymes, U/IAlanine aminotransferase29,5 \pm 1,0Aspartate transaminase27,9 \pm 1,1							
Deformation of the gallbladderbody817,4neck613,0s-like2860,9contour48,7Biochemical indicators of blood1Lipidogram (mg/100m)1IndicatorM±mtotal lipids659,3±17,3phospholipids159,9±4,7free cholesterol49,9±2,2non-esterified fatty acids58,8±6,1triglycerides175,2±9,7cholesterol esters101,3±4,5Bilirubin, mmol/I17,9±3,4indirect fraction7,8±1,1Enzymes, U/IEnzymes, U/IAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1		15					
body817,4neck613,0s-like2860,9contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/l $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/l $29,5\pm1,0$ Alanine aminotransferase $27,9\pm1,1$		1	2,2				
neck613,0s-like2860,9contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/lIndirect fractiondirect fraction $7,8\pm1,1$ Enzymes, U/lIndirect fractionAlanine aminotransferase $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$		adder					
s-like2860,9contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/IIndirect fractiontotal bilirubin $24,8\pm6,1$ direct fraction $7,8\pm1,1$ Enzymes, U/IIndirect fractionAlanine aminotransferase $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$		-					
contour48,7Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/IIndirect fractiontotal bilirubin $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/IIndirect fractionAlanine aminotransferase $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$		6					
Biochemical indicators of bloodLipidogram (mg/100ml)IndicatorM±mtotal lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/I $Alanine aminotransferase$ Aspartate transaminase $27,9\pm1,1$	s-like	28					
Lipidogram (mg/100ml)Indicator $M\pm m$ total lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/I $Alanine aminotransferase$ Aspartate transaminase $27,9\pm1,1$			8,7				
Indicator $M\pm m$ total lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/I $29,5\pm1,0$ Alanine aminotransferase $27,9\pm1,1$							
total lipids $659,3\pm17,3$ phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/I $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$							
phospholipids $159,9\pm4,7$ free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/I $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$							
free cholesterol $49,9\pm2,2$ non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/I $24,8\pm6,1$ total bilirubin $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/I $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$							
non-esterified fatty acids $58,8\pm6,1$ triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/l $24,8\pm6,1$ total bilirubin $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/l $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$							
triglycerides $175,2\pm9,7$ cholesterol esters $101,3\pm4,5$ Bilirubin, mmol/l $24,8\pm6,1$ total bilirubin $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/l $29,5\pm1,0$ Alanine aminotransferase $27,9\pm1,1$							
cholesterol esters101,3±4,5Bilirubin, mmol/ltotal bilirubin24,8±6,1direct fraction17,9±3,4indirect fraction7,8±1,1Enzymes, U/lAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1			/				
Bilirubin, mmol/ltotal bilirubin24,8±6,1direct fraction17,9±3,4indirect fraction7,8±1,1Enzymes, U/lAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1							
total bilirubin $24,8\pm6,1$ direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/IAlanine aminotransferase $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$			±4,5				
direct fraction $17,9\pm3,4$ indirect fraction $7,8\pm1,1$ Enzymes, U/IAlanine aminotransferase $29,5\pm1,0$ Aspartate transaminase $27,9\pm1,1$							
indirect fraction7,8±1,1Enzymes, U/IAlanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1							
indirect fraction7,8±1,1Enzymes, U/IImage: Constraint of the second s		17,9±3,4					
Alanine aminotransferase29,5±1,0Aspartate transaminase27,9±1,1		7,8±1,1					
Aspartate transaminase 27,9±1,1							
Alkaline phosphatase 90.9 ± 5.7							
	Alkaline phosphatase	90,9=	±5,7				

Оригінальні дослідження

Zinc deficiency in the blood plasma of children with biliary tract dysfunction was found in 53 cases (76.8%), while in the comparison group, a decrease in zinc level was observed in only 2 children (8%). The lowest levels of zinc in the blood plasma were observed in children suffering from GSD (Table 3). gastrointestinal diseases was 1.87 times lower than in children of the comparison group and 1.37 times lower than in children with hyperkinetic gallbladder dysfunction, while the probable difference between these indicators in children, there were no patients with GSD and children with hypotonic type of gallbladder dysfunction (p<0.05).

Thus, the plasma concentration of zinc in children with




Fig. 2. Concentration of zinc in blood plasma of examined children depending on age and gender

Concentration of zinc in blood plasma of children with pathology of the biliary tract									
	Indicator	Children	Children with GBD	Children with GBD	CG,				
		with GSD,	(hyperkinetic type),	(hypokinetic type),	n=25				
		n=46	n=38	n=31					
	Zinc, mg/l	2,13±0,44*	2,92±0,37	2,32±0,53*	3,98±0,69				
	Notes: GSD - gallstone disease GBD - gallbladder dysfunction CG- comparison								

Notes: GSD - gallstone disease, GBD - gallbladder dysfunction, CG- comparison group,

* - the difference in indicators is probable compared to the comparison group (p < 0.05).

Diseases of the biliary tract are one of the most common diseases of the digestive system [23]. Disorders of the motor-evacuation function of the gallbladder are diagnosed in 70–90% of children with diseases of the digestive organs [24, 25]. These violations lead to the development of organic pathology in the following periods of life, in particular, GSD [26]. Our studies have shown that the leading syndromes of the gastrointestinal tract were pain and dyspepsia. The second stage of gastrointestinal tract with single calculi, which were of pigment origin and most often localized in the gallbladder, was recorded more often. More than half of the examined children were characterized by s-shaped deformation of the gallbladder, which is consistent with the results of other studies [16, 18, 27].

When researching the zinc content in the blood plasma, its deficiency was proven, which can be interpreted as a certain disturbance in metabolic processes or a lack of this element in the child's body due to irrational nutrition [28, 29]. Since trace elements most often perform the functions of active centers or cofactors of enzymes in the body, without correcting their metabolic disorders, it is impossible to achieve the desired results in the prevention and treatment of most pathological conditions. A large number of studies are devoted to the study of one of the essential metals - zinc [30-32]. Zinc reserves in the human body are small. It is known that an adult contains only 1.5-2 g of zinc. Zinc is a cofactor of a large group of enzymes involved in protein and other types of metabolism, so it is necessary for the normal course of many biochemical processes [33]. Zinc is involved in the processes of cell division and differentiation, the formation of T-cell immunity, the functioning of dozens of enzymes, pancreatic insulin, the antioxidant enzyme superoxide dismutase, and the sex hormone dihydrocorticosterone. Zinc plays the most important role in the processes of skin regeneration, hair and nail growth, and sebaceous gland secretion [34]. Therefore, a reduced level of zinc in the body can lead to various consequences, in particular, to impaired coordination of the motility of bile secretion. Bile formation is closely dependent on the nature of the food consumed. The amount of secreted bile, the duration of its excretion depends on the composition of the food consumed [35]. Insufficient supply of micronutrients with food can lead to a deficiency of vital biologically active substances in the body, which sooner or later leads to the development of many common diseases [36], including disorders and diseases of the gastrointestinal tract and liver [37]. Due to the properties of zinc in certain concentrations to activate crystallization processes, zinc can be involved in the process of stone formation in the gall bladder [38]. Therefore, the detection of these disorders in the early stages of the pathogenetic development of GSD is important for the purpose of including zinc-containing foods or zinc-containing preparations in the diet for the correction of zinc concentration.

Prospects for further research. It is considered appropriate to further study the content of zinc in the diet

Original research

of children with gallstone disease, to discuss the need to include zinc-containing drugs for the treatment of cholelithiasis.

Conclusions. 1. The leading syndromes of gallstone disease in children were pain and dyspepsia. 2. Gallstone disease in children occurs against the background of gallbladder dysfunction with a predominance of the painful course, the formation of solitary bilirubin-derived concretions and minor changes in biochemical blood analysis. 3. The concentration of zinc in the blood plasma of children with gallstone disease is probably lower than in children of the comparison group and did not depend on age and gender.

References

1. Luk'ianenko OYu, Pantelieieva TI. Dysfunktsiia biliarnoho traktu v ditei: tradytsiini pidkhody y novi postulaty [Dysfunction of the biliary tract in children: traditional approaches and new postulates]. Gastroenterologiya. 2017;51(3):213-21. DOI: 10.22141/2308-2097.51.3.2017.112640. (in Ukrainian).

2. Stepanov YuM, Zavhorodnya NYu, Lukyanenko OYu, Yakhmur VB, Konenko IS, Petishko OP. Sonolohichni metody diahnostyky steatozu ta fibrozu pechinky v ditei [Sonological methods of diagnosing liver steatosis and fibrosis in children]. Gastroenterologiya. 2018;52(3):54-7. DOI: 10.22141/2308-2097.52.3.2018.141842. (in Ukrainian).

3. Diez S, Müller H, Weiss C, Schellerer V, Besendörfer M. Cholelithiasis and cholecystitis in children and adolescents: Does this increasing diagnosis require a common guideline for pediatricians and pediatric surgeons? BMC Gastroenterol. 2021;21(1):186. DOI:10.1186/s12876-021-01772-y.

4. Perisetti A, Raghavapuram S, Tharian B. Cholelithiasis in a patient with history of cholecystectomy. Clin Gastroenterol Hepatol. 2018;16(6):66-7. DOI: 10.1016/j.cgh.2017.08.045.

5. Frybova B, Drabek J, Lochmannova J, Douda L, Hlava S, Zemkova D, et al. Cholelithiasis and choledocholithiasis in children; risk factors for development. PLoS One. 2018;13(5):0196475. DOI: 10.1371/journal.pone.0196475.

6. Rothstein DH, Harmon CM. Gallbladder disease in children. Semin Pediatr Surg. 2016;25(4):225-31. DOI: 10.1053/j.sempedsurg. 2016.05.005.

7. Cabrera Chamorro CC, Pabón Arteaga JS, Caicedo Paredes CA, Cabrera Bravo N, Villamil Giraldo CE, Chávez Betancourt G, et al. Cholelithiasis and associated complications in pediatric patients. Cir Pediatr. 2020;33:172-76.

8. Feldman AG, Sokol RJ. Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention. Neoreviews. 2021;22(12):819-36. DOI: 10.1542/neo.22-12-e819.

9. Quelhas P, Jacinto J, Cerski C, Oliveira R, Oliveira J, Carvalho E, et al. Protocols of Investigation of Neonatal Cholestasis-A Critical Appraisal. Healthcare (Basel). 2022;10(10):2012. DOI: 10.3390/healthcare10102012.

10. Wehrman A, Lee CK. The cholestatic infant: updates on diagnosis and genetics. Curr Opin Pediatr. 2022;34(5):491-95. DOI: 10.1097/MOP.00000000001156.

11. Zdanowicz K, Daniluk J, Lebensztejn DM, Daniluk U. The Etiology of Cholelithiasis in Children and Adolescents-A Literature Review. Int J Mol Sci. 2022;23(21):13376. DOI: 10.3390/ijms232113376.

12. Frybova B, Drabek J, Lochmannova J, Douda L, Hlava S, Zemkova D, et al. Cholelithiasis and choledocholithiasis in children; risk factors for development. PLoS One. 2018;13(5):0196475. DOI: 10.1371/journal.pone.0196475.

13. Stock MR, Fine RO, Rivas Y, Levin TL. Magnetic

resonance imaging following the demonstration of a normal common bile duct on ultrasound in children with suspected choledocholithiasis: what is the benefit? Pediatric Radiol. 2023;53(3):358-66. DOI: 10.1007/s00247-022-05537-x.

14. Lia E, Amri K. Cholelithiasis in children: A characteristic study. Med J Malaysia. 2022;77(1):59-61.

15. Bhaumik K. Asymptomatic Cholelithiasis in Children: Management Dilemma. J Indian Assoc Pediatr Surg. 2021;26(4):228-33. DOI: 10.4103/jiaps.JIAPS_107_20.

16. Martin WT, Stewart K, Sarwar Z, Kennedy R, Quang C, Albrecht R, et al. Clinical diagnosis of cholecystitis in emergency department patients with cholelithiasis is indication for urgent cholecystectomy: A comparison of clinical, ultrasound, and pathologic diagnosis. Am J Surg. 2022;224(1 Pt A):80-4. DOI: 10.1016/j.amjsurg.2022.02.051.

17. Jacobson JC, Bosley ME, Gaffley MW, Davis JS, Neff LP. Pediatric Normokinetic Biliary Dyskinesia: Pain with Cholecystokinin on Hepatobiliary Iminodiacetic Acid Scan Predictive of Symptom Resolution After Cholecystectomy. J Laparoendosc Adv Surg Tech A. 2022;32(7):794-99. DOI: 10.1089/lap.2021.0349.

18. Osterode W, Falkenberg G, Wrba F. Copper and Trace Elements in Gallbladder form Patients with Wilson's Disease Imaged and Determined by Synchrotron X-ray Fluorescence. J Imaging. 2021;7(12):261. DOI: 10.3390/jimaging7120261.

19. Warthon-Medina M, Moran VH, Stammers AL, Dillon S, Qualter P, Nissensohn M, et al. Zinc intake, status and indices of cognitive function in adults and children: a systematic review and meta-analysis. Eur J Clin Nutr. 2015;69(6):649-61. DOI: 10.1038/ejcn.2015.60.

20. Ruangritchankul S, Sumananusorn C, Sirivarasai J, Monsuwan W, Sritara P. Association between Dietary Zinc Intake, Serum Zinc Level and Multiple Comorbidities in Older Adults. Nutrients. 2023;15(2):322. DOI: 10.3390/nu15020322.

21. Order of the Ministry of Health of Ukraine dated January 29, 2013, No. 59 «On approval of unified clinical protocols for medical care for children with diseases of the digestive system».

22. Kyrana E, Rees D, Lacaille F, Fitzpatrick E, Davenport M, Heaton N, et al. Clinical management of sickle cell liver disease in children and young adults. Arch Dis Child. 2021;106(4):315-20. DOI: 10.1136/archdischild-2020-319778.

23. Marushko YuV, Nahorna KI. Defitsyt zaliza ta biliarna dysfunktsiia u ditei [Iron deficiency and biliary dysfunction in children]. Dytiachyi likar. 2017;4:5-9. (in Ukrainian).

24. Punia RP, Garg S, Bisht B, Dalal U, Mohan H. Clinicopathological spectrum of gallbladder disease in children. Acta Paediatr. 2010;99(10):1561-64. DOI: 10.1111/j.1651-2227.2010.01876.x.

25. Mahida JB, Sulkowski JP, Cooper JN, King AP, Deans KJ, King DR, et al. Prediction of symptom improvement in children with biliary dyskinesia. J Surg Res. 2015;198(2):393-9. DOI: 10.1016/j.jss.2015.03.056.

26. Blackwood B, Grabowski J. Chronic cholecystitis in the pediatric population: an underappreciated disease process. Gastroenterol Hepatol Bed Bench. 2017;10(2):125-30. DOI: 10.22037/GHFBB.V0I0.980.

27. Escobedo-Monge MF, Torres-Hinojal MC, Barrado E, Escobedo-Monge MA, Marugán-Miguelsanz JM. Zinc Nutritional Status in a Series of Children with Chronic Diseases: A Cross-Sectional Study. Nutrients. 2021;13(4):1121. DOI: 10.3390/nu13041121.

28. Kubota M, Matsuda S, Matsuda M, Yamamoto K, Yoshii Y. Association of Serum Zinc Level with severity of chronic kidney disease in diabetic patients: a cross-sectional study. BMC Nephrology. 2022;23(1):407. DOI: 10.1186/s12882-022-03040-X.

Оригінальні дослідження

29. Ogawa Y, Kinoshita M, Shimada S, Kawamura T. Zinc and Skin Disorders. Nutrients. 2018;10(2):199. DOI: 10.3390/nu10020199.

30. Kambe T, Tsuji T, Hashimoto A, Itsumura N. The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. Physiol Rev. 2015;95(3):749-84. DOI: 10.1152/physrev.00035.2014.

31. Ruangritchankul S, Sumananusorn C, Sirivarasai J, Monsuwan W, Sritara P. Association between Dietary Zinc Intake, Serum Zinc Level and Multiple Comorbidities in Older Adults. Nutrients. 2023;15(2):322. DOI: 10.3390/nu15020322.

32. Kim J, Lee J, Ryu MS. Cellular Zinc Deficiency Impairs Heme Biosynthesis in Developing Erythroid Progenitors. Nutrients. 2023;15(2):281. DOI: 10.3390/nu15020281.

33. Escobedo-Monge MF, Barrado E, Parodi-Román J, Escobedo-Monge MA, Torres-Hinojal MC, Marugán-Miguelsanz JM. Copper and Copper/Zn Ratio in a Series of

Children with Chronic Diseases: A Cross-Sectional Study. Nutrients. 2021;13(10):3578. DOI: 10.3390/nu13103578.

34. Jazaeri F, Sheibani M, Nezamoleslami S, Moezi L, Dehpour AR. Current Models for Predicting Drug-induced Cholestasis: The Role of Hepatobiliary Transport System. Iran J Pharm Res. 2021;20(2):1-21. DOI: 10.22037/ijpr.2020.113362.14254.

35. Zoroddu MA, Aaseth J, Crisponi G, Medici S, Peana M, Nurchi VM. The essential metals for humans: a brief overview. J Inorg Biochem. 2019;195:120-29. DOI: 10.1016/j.jinorgbio.2019.03.013.

36. Himoto T, Masaki T. Associations between Zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients. 2018;10(1):88. DOI: 10.3390/nu10010088.

37. Bakhotmah MA. The concentration of trace elements in human lithogenic bile. HPB Surg. 1996;9(3):161-64. DOI:10. 1155/1996/26323.

Відомості про авторів

Sorokman TV - MD, DSc, Professor at the Department of Pediatrics and Medical Genetics, Bukovinian State Medical University, Cherniv**tsi**, Ukraine. ORCID ID: https://orcid.org/0000-0001-7615-346.

Ostapchuk VG – PhD, Associate Professor at the Department of Pediatrics and Medical Genetics, Bukovinian State Medical University. ORCID ID https://orcid.org/ 0000-0002-2595-4770.

Відомості про авторів

Сорокман Таміла Василівна – д-р мед. наук, професор кафедри педіатрії та медичної генетики Буковинського державного медичного університету, м. Чернівці, Україна. ORCIDID: https://orcid.org0000-0001-7615-3466. Остапчук Валентина Григорівна – канд.мед.наук, асистент кафедри педіатрії та медичної генетики Буковинського державного медичного університету, м. Чернівці, Україна. ORCID ID https://orcid.org/ 0000-0002-2595-4770

Надійшла до редакції 05.02.23 Рецензент – проф. Сокольник О.Д. © T.V. Sorokman, V.G. Ostapchuk, 2023